An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as Well as the Pharmacokinetic Profile of Oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo in Women With Overactive Bladder
An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as Well as the Pharmacokinetic Profile of Oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo in Women With Overactive Bladder
This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.
Inclusion Criteria:
Exclusion Criteria:
Av Córdoba 2424, Buenos Aires 1120, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1406CPC, Argentina
Ciudad de Buenos Aires, Buenos Aires C1425BGV, Argentina
Hagenow, Brandenburg 19230, Germany
Leipzg, Saxony 04109, Germany